Cargando…

Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies

BACKGROUND: Efforts are underway to eliminate trachoma as a public health problem by 2020. Programmatic guidelines are based on clinical signs that correlate poorly with Chlamydia trachomatis (Ct) infection in post-treatment and low-endemicity settings. Age-specific seroprevalence of anti Ct Pgp3 an...

Descripción completa

Detalles Bibliográficos
Autores principales: Migchelsen, Stephanie J., Martin, Diana L., Southisombath, Khamphoua, Turyaguma, Patrick, Heggen, Anne, Rubangakene, Peter Paul, Joof, Hassan, Makalo, Pateh, Cooley, Gretchen, Gwyn, Sarah, Solomon, Anthony W., Holland, Martin J., Courtright, Paul, Willis, Rebecca, Alexander, Neal D. E., Mabey, David C. W., Roberts, Chrissy h.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242428/
https://www.ncbi.nlm.nih.gov/pubmed/28099433
http://dx.doi.org/10.1371/journal.pntd.0005230
_version_ 1782496329777283072
author Migchelsen, Stephanie J.
Martin, Diana L.
Southisombath, Khamphoua
Turyaguma, Patrick
Heggen, Anne
Rubangakene, Peter Paul
Joof, Hassan
Makalo, Pateh
Cooley, Gretchen
Gwyn, Sarah
Solomon, Anthony W.
Holland, Martin J.
Courtright, Paul
Willis, Rebecca
Alexander, Neal D. E.
Mabey, David C. W.
Roberts, Chrissy h.
author_facet Migchelsen, Stephanie J.
Martin, Diana L.
Southisombath, Khamphoua
Turyaguma, Patrick
Heggen, Anne
Rubangakene, Peter Paul
Joof, Hassan
Makalo, Pateh
Cooley, Gretchen
Gwyn, Sarah
Solomon, Anthony W.
Holland, Martin J.
Courtright, Paul
Willis, Rebecca
Alexander, Neal D. E.
Mabey, David C. W.
Roberts, Chrissy h.
author_sort Migchelsen, Stephanie J.
collection PubMed
description BACKGROUND: Efforts are underway to eliminate trachoma as a public health problem by 2020. Programmatic guidelines are based on clinical signs that correlate poorly with Chlamydia trachomatis (Ct) infection in post-treatment and low-endemicity settings. Age-specific seroprevalence of anti Ct Pgp3 antibodies has been proposed as an alternative indicator of the need for intervention. To standardise the use of these tools, it is necessary to develop an analytical approach that performs reproducibly both within and between studies. METHODOLOGY: Dried blood spots were collected in 2014 from children aged 1–9 years in Laos (n = 952) and Uganda (n = 2700) and from people aged 1–90 years in The Gambia (n = 1868). Anti-Pgp3 antibodies were detected by ELISA. A number of visual and statistical analytical approaches for defining serological status were compared. PRINCIPAL FINDINGS: Seroprevalence was estimated at 11.3% (Laos), 13.4% (Uganda) and 29.3% (The Gambia) by visual inspection of the inflection point. The expectation-maximisation algorithm estimated seroprevalence at 10.4% (Laos), 24.3% (Uganda) and 29.3% (The Gambia). Finite mixture model estimates were 15.6% (Laos), 17.1% (Uganda) and 26.2% (The Gambia). Receiver operating characteristic (ROC) curve analysis using a threshold calibrated against external reference specimens estimated the seroprevalence at 6.7% (Laos), 6.8% (Uganda) and 20.9% (The Gambia) when the threshold was set to optimise Youden’s J index. The ROC curve analysis was found to estimate seroprevalence at lower levels than estimates based on thresholds established using internal reference data. Thresholds defined using internal reference threshold methods did not vary substantially between population samples. CONCLUSIONS: Internally calibrated approaches to threshold specification are reproducible and consistent and thus have advantages over methods that require external calibrators. We propose that future serological analyses in trachoma use a finite mixture model or expectation-maximisation algorithm as a means of setting the threshold for ELISA data. This will facilitate standardisation and harmonisation between studies and eliminate the need to establish and maintain a global calibration standard.
format Online
Article
Text
id pubmed-5242428
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-52424282017-02-06 Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies Migchelsen, Stephanie J. Martin, Diana L. Southisombath, Khamphoua Turyaguma, Patrick Heggen, Anne Rubangakene, Peter Paul Joof, Hassan Makalo, Pateh Cooley, Gretchen Gwyn, Sarah Solomon, Anthony W. Holland, Martin J. Courtright, Paul Willis, Rebecca Alexander, Neal D. E. Mabey, David C. W. Roberts, Chrissy h. PLoS Negl Trop Dis Research Article BACKGROUND: Efforts are underway to eliminate trachoma as a public health problem by 2020. Programmatic guidelines are based on clinical signs that correlate poorly with Chlamydia trachomatis (Ct) infection in post-treatment and low-endemicity settings. Age-specific seroprevalence of anti Ct Pgp3 antibodies has been proposed as an alternative indicator of the need for intervention. To standardise the use of these tools, it is necessary to develop an analytical approach that performs reproducibly both within and between studies. METHODOLOGY: Dried blood spots were collected in 2014 from children aged 1–9 years in Laos (n = 952) and Uganda (n = 2700) and from people aged 1–90 years in The Gambia (n = 1868). Anti-Pgp3 antibodies were detected by ELISA. A number of visual and statistical analytical approaches for defining serological status were compared. PRINCIPAL FINDINGS: Seroprevalence was estimated at 11.3% (Laos), 13.4% (Uganda) and 29.3% (The Gambia) by visual inspection of the inflection point. The expectation-maximisation algorithm estimated seroprevalence at 10.4% (Laos), 24.3% (Uganda) and 29.3% (The Gambia). Finite mixture model estimates were 15.6% (Laos), 17.1% (Uganda) and 26.2% (The Gambia). Receiver operating characteristic (ROC) curve analysis using a threshold calibrated against external reference specimens estimated the seroprevalence at 6.7% (Laos), 6.8% (Uganda) and 20.9% (The Gambia) when the threshold was set to optimise Youden’s J index. The ROC curve analysis was found to estimate seroprevalence at lower levels than estimates based on thresholds established using internal reference data. Thresholds defined using internal reference threshold methods did not vary substantially between population samples. CONCLUSIONS: Internally calibrated approaches to threshold specification are reproducible and consistent and thus have advantages over methods that require external calibrators. We propose that future serological analyses in trachoma use a finite mixture model or expectation-maximisation algorithm as a means of setting the threshold for ELISA data. This will facilitate standardisation and harmonisation between studies and eliminate the need to establish and maintain a global calibration standard. Public Library of Science 2017-01-18 /pmc/articles/PMC5242428/ /pubmed/28099433 http://dx.doi.org/10.1371/journal.pntd.0005230 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication.
spellingShingle Research Article
Migchelsen, Stephanie J.
Martin, Diana L.
Southisombath, Khamphoua
Turyaguma, Patrick
Heggen, Anne
Rubangakene, Peter Paul
Joof, Hassan
Makalo, Pateh
Cooley, Gretchen
Gwyn, Sarah
Solomon, Anthony W.
Holland, Martin J.
Courtright, Paul
Willis, Rebecca
Alexander, Neal D. E.
Mabey, David C. W.
Roberts, Chrissy h.
Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies
title Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies
title_full Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies
title_fullStr Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies
title_full_unstemmed Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies
title_short Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies
title_sort defining seropositivity thresholds for use in trachoma elimination studies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242428/
https://www.ncbi.nlm.nih.gov/pubmed/28099433
http://dx.doi.org/10.1371/journal.pntd.0005230
work_keys_str_mv AT migchelsenstephaniej definingseropositivitythresholdsforuseintrachomaeliminationstudies
AT martindianal definingseropositivitythresholdsforuseintrachomaeliminationstudies
AT southisombathkhamphoua definingseropositivitythresholdsforuseintrachomaeliminationstudies
AT turyagumapatrick definingseropositivitythresholdsforuseintrachomaeliminationstudies
AT heggenanne definingseropositivitythresholdsforuseintrachomaeliminationstudies
AT rubangakenepeterpaul definingseropositivitythresholdsforuseintrachomaeliminationstudies
AT joofhassan definingseropositivitythresholdsforuseintrachomaeliminationstudies
AT makalopateh definingseropositivitythresholdsforuseintrachomaeliminationstudies
AT cooleygretchen definingseropositivitythresholdsforuseintrachomaeliminationstudies
AT gwynsarah definingseropositivitythresholdsforuseintrachomaeliminationstudies
AT solomonanthonyw definingseropositivitythresholdsforuseintrachomaeliminationstudies
AT hollandmartinj definingseropositivitythresholdsforuseintrachomaeliminationstudies
AT courtrightpaul definingseropositivitythresholdsforuseintrachomaeliminationstudies
AT willisrebecca definingseropositivitythresholdsforuseintrachomaeliminationstudies
AT alexandernealde definingseropositivitythresholdsforuseintrachomaeliminationstudies
AT mabeydavidcw definingseropositivitythresholdsforuseintrachomaeliminationstudies
AT robertschrissyh definingseropositivitythresholdsforuseintrachomaeliminationstudies